• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国癌症统计数据:2010 年的发病率、死亡率、生存率和流行率。

Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010.

机构信息

The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Korea.

出版信息

Cancer Res Treat. 2013 Mar;45(1):1-14. doi: 10.4143/crt.2013.45.1.1. Epub 2013 Mar 31.

DOI:10.4143/crt.2013.45.1.1
PMID:23613665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3629358/
Abstract

PURPOSE

This article gives an overview of nationwide cancer statistics, including incidence, mortality, survival and prevalence, and their trends in Korea based on 2010 cancer incidence data.

MATERIALS AND METHODS

Incidence data from 1993 to 2010 were obtained from the Korea National Cancer Incidence Database, and vital status was followed until 31 December 2011. Mortality data from 1983 to 2010 were obtained from Statistics Korea. Crude and age-standardized rates for incidence, mortality, prevalence, and relative survival were calculated.

RESULTS

In total, 202,053 cancer cases and 72,046 cancer deaths occurred during 2010, and 960,654 prevalent cancer cases were identified in Korea as of 1 January 2011. The incidence of all cancers combined showed an annual increase of 3.3% from 1999 to 2010. The incidences of liver and cervical cancers have decreased while those of thyroid, breast, prostate and colorectal cancers have increased. Notably, thyroid cancer, which is the most common cancer in Korea, increased by 24.2% per year rapidly in both sexes. The mortality of all cancers combined showed a decrease by 2.7% annually from 2002 to 2010. Five-year relative survival rates of patients who were diagnosed with cancer from 2006 to 2011 had improved by 22.9% compared with those from 1993 to 1995.

CONCLUSION

While the overall cancer incidence in Korea has increased rapidly, age-standardized cancer mortality rates have declined since 2002 and survival has improved.

摘要

目的

本文概述了韩国全国范围内的癌症统计数据,包括发病率、死亡率、生存率和患病率及其趋势,这些数据基于 2010 年的癌症发病率数据。

材料和方法

1993 年至 2010 年的发病率数据来自韩国国家癌症发病率数据库,生存状态一直跟踪到 2011 年 12 月 31 日。1983 年至 2010 年的死亡率数据来自韩国统计局。计算了发病率、死亡率、患病率和相对生存率的粗率和年龄标准化率。

结果

2010 年共发生 202053 例癌症病例和 72046 例癌症死亡病例,截至 2011 年 1 月 1 日,韩国有 960654 例现患癌症病例。1999 年至 2010 年,所有癌症的发病率每年增加 3.3%。肝癌和宫颈癌的发病率有所下降,而甲状腺癌、乳腺癌、前列腺癌和结直肠癌的发病率有所上升。值得注意的是,甲状腺癌是韩国最常见的癌症,在两性中均以每年 24.2%的速度迅速增加。2002 年至 2010 年,所有癌症的死亡率每年下降 2.7%。2006 年至 2011 年诊断出癌症的患者的 5 年相对生存率与 1993 年至 1995 年相比提高了 22.9%。

结论

尽管韩国的总体癌症发病率迅速上升,但自 2002 年以来,年龄标准化的癌症死亡率下降,生存率提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/b53f1d009e7d/crt-45-1-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/c70c5dabd9cf/crt-45-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/a2066ec6b40e/crt-45-1-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/13517fb0be75/crt-45-1-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/b7534cbca1f1/crt-45-1-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/b53f1d009e7d/crt-45-1-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/c70c5dabd9cf/crt-45-1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/a2066ec6b40e/crt-45-1-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/13517fb0be75/crt-45-1-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/b7534cbca1f1/crt-45-1-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a3/3629358/b53f1d009e7d/crt-45-1-g005.jpg

相似文献

1
Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010.韩国癌症统计数据:2010 年的发病率、死亡率、生存率和流行率。
Cancer Res Treat. 2013 Mar;45(1):1-14. doi: 10.4143/crt.2013.45.1.1. Epub 2013 Mar 31.
2
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011.韩国癌症统计数据:2011 年的发病率、死亡率、生存率和流行率。
Cancer Res Treat. 2014 Apr;46(2):109-23. doi: 10.4143/crt.2014.46.2.109. Epub 2014 Apr 22.
3
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012.韩国癌症统计数据:2012年的发病率、死亡率、生存率及患病率
Cancer Res Treat. 2015 Apr;47(2):127-41. doi: 10.4143/crt.2015.060. Epub 2015 Mar 3.
4
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009.韩国癌症统计数据:2009 年的发病率、死亡率、生存率和患病率。
Cancer Res Treat. 2012 Mar;44(1):11-24. doi: 10.4143/crt.2012.44.1.11. Epub 2012 Mar 31.
5
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013.韩国癌症统计数据:2013年的发病率、死亡率、生存率及患病率
Cancer Res Treat. 2016 Apr;48(2):436-50. doi: 10.4143/crt.2016.089. Epub 2016 Mar 3.
6
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015.韩国癌症统计数据:2015 年发病率、死亡率、生存率和流行率。
Cancer Res Treat. 2018 Apr;50(2):303-316. doi: 10.4143/crt.2018.143. Epub 2018 Mar 21.
7
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014.韩国癌症统计数据:2014年的发病率、死亡率、生存率及患病率
Cancer Res Treat. 2017 Apr;49(2):292-305. doi: 10.4143/crt.2017.118. Epub 2017 Mar 9.
8
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018.《韩国癌症统计数据:2018 年发病率、死亡率、生存率和流行率》
Cancer Res Treat. 2021 Apr;53(2):301-315. doi: 10.4143/crt.2021.291. Epub 2021 Mar 17.
9
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008.韩国癌症统计数据:2008 年的发病率、死亡率、生存率和患病率。
Cancer Res Treat. 2011 Mar;43(1):1-11. doi: 10.4143/crt.2011.43.1.1. Epub 2011 Mar 31.
10
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017.韩国癌症统计数据:2017 年发病率、死亡率、生存率和患病率。
Cancer Res Treat. 2020 Apr;52(2):335-350. doi: 10.4143/crt.2020.206. Epub 2020 Mar 16.

引用本文的文献

1
Clinicopathological features and outcomes in patients with concurrent medullary and papillary thyroid carcinoma.甲状腺髓样癌和乳头状癌并存患者的临床病理特征及预后
Front Endocrinol (Lausanne). 2025 Aug 11;16:1625989. doi: 10.3389/fendo.2025.1625989. eCollection 2025.
2
Recent 5‑year trends in biliary tract cancer survival rates: An analytical big data survey.胆道癌生存率的近5年趋势:一项大数据分析调查。
Med Int (Lond). 2025 Jan 10;5(2):15. doi: 10.3892/mi.2025.214. eCollection 2025 Mar-Apr.
3
Perspectives on delivering sexual and reproductive health and rights information and services to young people: focus group discussions with civil society organizations in the Democratic Republic of Congo.

本文引用的文献

1
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009.韩国癌症统计数据:2009 年的发病率、死亡率、生存率和患病率。
Cancer Res Treat. 2012 Mar;44(1):11-24. doi: 10.4143/crt.2012.44.1.11. Epub 2012 Mar 31.
2
Current status of thyroid cancer screening in Korea: results from a nationwide interview survey.韩国甲状腺癌筛查的现状:一项全国性访谈调查的结果
Asian Pac J Cancer Prev. 2011;12(7):1657-63.
3
Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database.
向年轻人提供性与生殖健康及权利信息和服务的观点:与刚果民主共和国民间社会组织的焦点小组讨论
Glob Health Action. 2024 Dec 31;17(1):2429631. doi: 10.1080/16549716.2024.2429631. Epub 2025 Jan 17.
4
Sex-specific differences in colorectal cancer: A multicenter retrospective cohort study.结直肠癌的性别特异性差异:一项多中心回顾性队列研究。
Cancer Rep (Hoboken). 2023 Aug;6(8):e1845. doi: 10.1002/cnr2.1845. Epub 2023 Jun 22.
5
Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study.亚洲国家甲状腺癌的生存率:一项系统评价和荟萃分析研究。
Endocrine. 2023 Nov;82(2):237-249. doi: 10.1007/s12020-023-03408-5. Epub 2023 Jun 3.
6
Risks of Leukemia in Various Industrial Groups in Korea: A Retrospective National Cohort Study.韩国不同工业群体的白血病风险:一项回顾性全国队列研究。
Int J Environ Res Public Health. 2023 Jan 9;20(2):1187. doi: 10.3390/ijerph20021187.
7
Bioelectrical impedance spectroscopy can assist to identify the parathyroid gland during thyroid surgery.生物电阻抗频谱分析有助于在甲状腺手术中识别甲状旁腺。
Front Endocrinol (Lausanne). 2022 Sep 15;13:963520. doi: 10.3389/fendo.2022.963520. eCollection 2022.
8
Health Care Utilization and Anti-Cancer Drug Expenditure for Six Solid Cancers in Korea From 2007 to 2019.2007年至2019年韩国六种实体癌的医疗保健利用情况及抗癌药物支出
Front Oncol. 2022 Jun 27;12:862173. doi: 10.3389/fonc.2022.862173. eCollection 2022.
9
Impact of loss of skeletal muscle mass within 6-12 months after gastrectomy and S1 adjuvant chemotherapy on the survival prognosis of elderly patients with gastric cancer.胃癌患者术后 6-12 个月内骨骼肌量丢失及 S1 辅助化疗对其生存预后的影响。
Surg Today. 2022 Oct;52(10):1472-1483. doi: 10.1007/s00595-022-02489-5. Epub 2022 Apr 8.
10
Impact of Dyslipidemia on the Risk of Second Cancer in Thyroid Cancer Patients: A Korean National Cohort Study.血脂异常对甲状腺癌患者二次癌症风险的影响:一项韩国全国队列研究。
Ann Surg Oncol. 2021 Aug;28(8):4373-4384. doi: 10.1245/s10434-020-09570-8. Epub 2021 Jan 22.
韩国 1999~2001 年全国癌症发病率;首次使用全国癌症发病率数据库的结果。
Cancer Res Treat. 2005 Dec;37(6):325-31. doi: 10.4143/crt.2005.37.6.325. Epub 2005 Dec 31.
4
Nationwide cancer incidence in Korea, 2003-2005.韩国 2003-2005 年全国癌症发病率。
Cancer Res Treat. 2009 Sep;41(3):122-31. doi: 10.4143/crt.2009.41.3.122. Epub 2009 Sep 28.
5
Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.1980 - 2005年美国按人口统计学和肿瘤特征划分的甲状腺癌发病率上升情况
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91. doi: 10.1158/1055-9965.EPI-08-0960. Epub 2009 Feb 24.
6
Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis.1990年至2009年11个欧洲人群的癌症生存率趋势:基于模型的分析。
Ann Oncol. 2009 Mar;20(3):564-73. doi: 10.1093/annonc/mdn639. Epub 2008 Dec 9.
7
Cancer survival in Korea 1993-2002: a population-based study.韩国1993 - 2002年癌症生存率:一项基于人群的研究。
J Korean Med Sci. 2007 Sep;22 Suppl(Suppl):S5-S10. doi: 10.3346/jkms.2007.22.S.S5.
8
Measuring the burden of disease in Korea.衡量韩国的疾病负担。
J Korean Med Sci. 2007 Jun;22(3):518-23. doi: 10.3346/jkms.2007.22.3.518.
9
Interpreting trends in cancer patient survival.解读癌症患者的生存趋势。
J Intern Med. 2006 Aug;260(2):103-17. doi: 10.1111/j.1365-2796.2006.01677.x.
10
Increasing incidence of thyroid cancer in the United States, 1973-2002.1973年至2002年美国甲状腺癌发病率上升情况。
JAMA. 2006 May 10;295(18):2164-7. doi: 10.1001/jama.295.18.2164.